QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
QL1701 demonstrated equivalent efficacy and similar safety to the reference trastuzumab when combined with docetaxel in the first-line treatment of patients with HER2-positive metastatic breast cancer, with similar PK and immunogenicity profiles.
Authors
- Q.-Y. Zhang
- C-J Li
- X. Kang
- H-P Li
- G H Song
- B-H Xu
- R-G Cai
- B-H Zhang
Institutions
- Qilu University of Technology (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Clinical Research (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103682
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28